AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 782888 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygenation (OHP) administered at 2.5 ATA in one or several series of daily exposure.
Number of subjects: 60
Study 782888 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control group).
Number of subjects: 60
Study 30633417 — intervention group
Group type: EXPERIMENTAL
Intervention: Crew Resource Management team training intervention
Number of subjects: 8123
Study 28597005 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with chlorhexidine (CHX)
Number of subjects: 28
Study 28597005 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with benzalkonium chloride (BAC)
Number of subjects: 28
Study 28597005 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified phosphoric acid with proanthocyanidins (PRO)
Number of subjects: 28
Study 28597005 — intervention group
Group type: COMPARATOR
Intervention: Conventional phosphoric acid (CON)
Number of subjects: 28
Study 25652442 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical vignettes
Number of subjects: 59
Study 25652442 — intervention group
Group type: COMPARATOR
Intervention: Standardized patients (unannounced visits)
Number of subjects: 59
Study 25076759 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin included in intensive care (administered intravenously at a speed of 140 drops (7 ml) per minute within 7 days, starting from the second day post-injury).
Number of subjects: 101
Study 25076759 — intervention group
Group type: COMPARATOR
Intervention: Standard intensive care without cytoflavin.
Number of subjects: 101
Study 23057058 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPDGF-BB + β-TCP
Number of subjects: 18
Study 23057058 — intervention group
Group type: COMPARATOR
Intervention: HA + β-TCP
Number of subjects: 18
Study 19097740 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) weight reduction intervention
Number of subjects: 53
Study 19097740 — intervention group
Group type: COMPARATOR
Intervention: Standard care with self-help manual
Number of subjects: 53
Study 19097740 — intervention group
Group type: COMPARATOR
Intervention: Standard care without self-help manual
Number of subjects: 53
Study 19097740 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation (SR) skills
Number of subjects: 53
Study 17574897 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 487
Study 17574897 — intervention group
Group type: COMPARATOR
Intervention: Dorsal position
Number of subjects: 487
Study 15352968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg po 1 h prior to surgery
Number of subjects: 70
Study 15352968 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo) + Ketoprofen 100 mg IV q 8 h for 24 h
Number of subjects: 70
Study 11203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2/Clearfil AP‐X (Group I, n = 10)
Number of subjects: 47
Study 11203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Resulcin AquaPrime + Monobond/MFR Merz (Group II, n = 9)
Number of subjects: 47
Study 11203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime&Bond 2.1/Dyract AP (Group III, n = 9)
Number of subjects: 47
Study 11203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/Z‐100 (Group IV, n = 10)
Number of subjects: 47
Study 11203774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecusit Primer AB‐Mono/Ecusit (Group V, n = 9)
Number of subjects: 47
Study 9668369 — intervention group
Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 0
Study 9668369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8115195 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg meperidine
Number of subjects: 84
Study 8115195 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 84
Study 3136636 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 33
Study 3136636 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 33
Study 3136636 — intervention group
Group type: EXPERIMENTAL
Intervention: Class IC agents (overall)
Number of subjects: 33
Study 1749015 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive smoking control intervention
Number of subjects: 200000
Study 1749015 — intervention group
Group type: COMPARATOR
Intervention: Comparison conditions (control group)
Number of subjects: 200000
Study 793706 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine, 2.5 mg/kg-d
Number of subjects: 9
Study 793706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31142536 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard action plan
Number of subjects: 2400
Study 31142536 — intervention group
Group type: EXPERIMENTAL
Intervention: Literacy-sensitive action plan
Number of subjects: 2400
Study 31142536 — intervention group
Group type: COMPARATOR
Intervention: Random allocation
Number of subjects: 2400
Study 31142536 — intervention group
Group type: COMPARATOR
Intervention: Allocation by health literacy screening tool
Number of subjects: 2400
Study 31142536 — intervention group
Group type: COMPARATOR
Intervention: Allocation by participant selection
Number of subjects: 2400
Study 28923573 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus trastuzumab and paclitaxel
Number of subjects: 50
Study 28923573 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel
Number of subjects: 50
Study 28923573 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus trastuzumab and paclitaxel (ER+ subgroup)
Number of subjects: 50
Study 28923573 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus trastuzumab and paclitaxel (ER+ subgroup)
Number of subjects: 50
Study 25885054 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled central venous catheter (TCVC) ± autologous arteriovenous fistula (AVF)
Number of subjects: 118
Study 25885054 — intervention group
Group type: COMPARATOR
Intervention: Early cannulation synthetic arteriovenous grafts (ecAVG) ± autologous arteriovenous fistula (AVF)
Number of subjects: 118
Study 24257457 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA Unique
Number of subjects: 30
Study 24257457 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Q
Number of subjects: 30
Study 24257457 — intervention group
Group type: EXPERIMENTAL
Intervention: CobraPLA
Number of subjects: 30
Study 21784378 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg added to Simvastatin 40 mg (E/S40)
Number of subjects: 786
Study 21784378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg (A)
Number of subjects: 786
Study 21784378 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5-10 mg (R)
Number of subjects: 786
Study 19410356 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation-assisted CPRII (AA-CPRII) instruction on cellular phones
Number of subjects: 80
Study 19410356 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional instruction)
Number of subjects: 80
Study 17507190 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release nifedipine tablets from DiSha (test)
Number of subjects: 20
Study 17507190 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release nifedipine tablets from GuoFeng (reference)
Number of subjects: 20
Study 15208493 — intervention group
Group type: EXPERIMENTAL
Intervention: 201Tl gated single photon emission computed tomographic (201Tl GSPECT) myocardial perfusion imaging
Number of subjects: 172
Study 15208493 — intervention group
Group type: COMPARATOR
Intervention: Equilibrium radionuclide angiography (ERNA)
Number of subjects: 172
Study 15487693 — intervention group
Group type: EXPERIMENTAL
Intervention: Light panretinal photocoagulation (LPRP)
Number of subjects: 50
Study 15487693 — intervention group
Group type: COMPARATOR
Intervention: Classic panretinal photocoagulation (CPRP)
Number of subjects: 50
Study 10024902 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT (2 mg 17 beta‐estradiol and 1 mg norethisterone acetate administered once daily without estriol)
Number of subjects: 27
Study 10024902 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined HRT
Number of subjects: 27
Study 8002124 — intervention group
Group type: EXPERIMENTAL
Intervention: GP/PL mixture (6.25 g GP to 0.75 g PL per 100 ml of water)
Number of subjects: 5
Study 8002124 — intervention group
Group type: COMPARATOR
Intervention: Glucose polymer solution (GP)
Number of subjects: 5
Study 3190813 — intervention group
Group type: EXPERIMENTAL
Intervention: Euphylong pellets
Number of subjects: 168
Study 30498758 — intervention group
Group type: EXPERIMENTAL
Intervention: Curene 500 mg once daily
Number of subjects: 50
Study 30498758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27465859 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin users (32 patients)
Number of subjects: 70
Study 27465859 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (38 patients)
Number of subjects: 70
Study 24447886 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based health promotion program
Number of subjects: 67
Study 24447886 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 22090466 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Stocking (ES) exerting a pressure of 23-32 mmHg
Number of subjects: 30
Study 22090466 — intervention group
Group type: COMPARATOR
Intervention: Inelastic Bandage (IB) exerting a high pressure
Number of subjects: 30
Study 20718226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning in pairs
Number of subjects: 62
Study 20718226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning in groups of 4
Number of subjects: 62
Study 20718226 — intervention group
Group type: COMPARATOR
Intervention: Individualistic learning
Number of subjects: 62
Study 18630533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with western medicine (acupuncture at specific points, intramuscular injection of Vit B1 and Vit B12, oral administration of ATP)
Number of subjects: 90
Study 18630533 — intervention group
Group type: COMPARATOR
Intervention: Simple acupuncture
Number of subjects: 90
Study 18630533 — intervention group
Group type: COMPARATOR
Intervention: Simple western medicine
Number of subjects: 90
Study 16046716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized grape powder (LGP) 36 g for 4 weeks
Number of subjects: 44
Study 12360108 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (225 mg twice daily)
Number of subjects: 50
Study 12360108 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beta-agonist salbutamol (200 microg)
Number of subjects: 50
Study 10548658 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rtPA)
Number of subjects: 0
Study 10548658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10548658 — intervention group
Group type: EXPERIMENTAL
Intervention: No hemorrhagic transformation
Number of subjects: 0
Study 8894912 — intervention group
Group type: EXPERIMENTAL
Intervention: Denser reinforcement schedules
Number of subjects: 8
Study 8894912 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral momentum predictions
Number of subjects: 8
Study 1997062 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate
Number of subjects: 20
Study 1997062 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (4%)
Number of subjects: 20
Study 6148572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine aerosol given by mask at a dose of 3500 or 7000 PFU
Number of subjects: 93
Study 6148572 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine aerosol given from a plastic bag at a dose of 7000 PFU
Number of subjects: 93
Study 6148572 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 400 PFU of vaccine intradermally in two divided doses
Number of subjects: 93
Study 6148572 — intervention group
Group type: EXPERIMENTAL
Intervention: 39 000 PFU of the virus subcutaneously
Number of subjects: 93
Study 6148572 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccinated children
Number of subjects: 93
Study 31786963 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term integrated rehabilitation
Number of subjects: 54
Study 31786963 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 54
Study 30196837 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (IFNB) treatment
Number of subjects: 88
Study 30196837 — intervention group
Group type: COMPARATOR
Intervention: No immunomodulatory treatment
Number of subjects: 88
Study 27184495 — intervention group
Group type: EXPERIMENTAL
Intervention: teneligliptin
Number of subjects: 45
Study 27184495 — intervention group
Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 45
Study 24362488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (40 mg) with combined oral contraceptive (1 mg norethisterone and 35 μg ethinyl estradiol)
Number of subjects: 22
Study 24362488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg)
Number of subjects: 22
Study 24362488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (20 mg)
Number of subjects: 22
Study 24362488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (40 mg)
Number of subjects: 22
Study 22985676 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 65
Study 20197194 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 116
Study 20197194 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 116
Study 17653486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum (109 CFU/day)
Number of subjects: 209
Study 17653486 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis Bb12 (109 CFU/day)
Number of subjects: 209
Study 17653486 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without viable bacteria)
Number of subjects: 209
Study 16283905 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial moisturizer with diazolidinyl urea concentrations ranging from 0.05% to 0.6%
Number of subjects: 0
Study 16283905 — intervention group
Group type: COMPARATOR
Intervention: Control group with the test product containing increasing preservative concentrations
Number of subjects: 0
Study 11857045 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT (50/50) supplemented with 100 mg DL-alpha-tocopherol/day
Number of subjects: 24
Study 11857045 — intervention group
Group type: COMPARATOR
Intervention: LCT
Number of subjects: 24
Study 10404024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) (cyclic estradiol/norethisterone acetate)
Number of subjects: 35
Study 10404024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 10404024 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 35
Study 7564082 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐31260 (1 mg/kg body wt)
Number of subjects: 0
Study 7564082 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐31260 (low dose unspecified)
Number of subjects: 0
Study 2188795 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg trazodone at night
Number of subjects: 228
Study 2188795 — intervention group
Group type: COMPARATOR
Intervention: 75 mg dothiepin at night
Number of subjects: 228
Study 2188795 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 228
Study 2188795 — intervention group
Group type: COMPARATOR
Intervention: Dothiepin
Number of subjects: 228
Study 6996149 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopyrine 240 mg plus phenylbutazone 130 mg (Tomanol)
Number of subjects: 40
Study 6996149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30883495 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice (2:1 speed ratio)
Number of subjects: 32
Study 30883495 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice (3 different speed ratios)
Number of subjects: 32
Study 30883495 — intervention group
Group type: COMPARATOR
Intervention: Both groups (constant and variable practice)
Number of subjects: 32
Study 28633773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) - 15 sessions (8 J/cm2; 830 nm)
Number of subjects: 60
Study 28633773 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions (2000 shocks)
Number of subjects: 60
Study 28633773 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic ultrasound (US) therapy - 15 sessions (1 mHz; 2 W/cm2)
Number of subjects: 60
Study 25934413 — intervention group
Group type: EXPERIMENTAL
Intervention: Community awareness programme (psycho-educational workshops and EIS link workers)
Number of subjects: 110
Study 25934413 — intervention group
Group type: EXPERIMENTAL
Intervention: Community awareness programme
Number of subjects: 110
Study 24098630 — intervention group
Group type: EXPERIMENTAL
Intervention: Training towards negative cues
Number of subjects: 129
Study 24098630 — intervention group
Group type: EXPERIMENTAL
Intervention: Training towards positive cues
Number of subjects: 129
Study 24098630 — intervention group
Group type: COMPARATOR
Intervention: Control training condition
Number of subjects: 129
Study 21813443 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL of PRP
Number of subjects: 28
Study 21813443 — intervention group
Group type: COMPARATOR
Intervention: 3 mL of autologous blood
Number of subjects: 28
Study 21813443 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PRP and autologous blood)
Number of subjects: 28
Study 19764189 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme designed to reduce the risk of occupational injuries
Number of subjects: 0
Study 19764189 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 17538085 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (decompressive laminectomy with or without fusion)
Number of subjects: 304
Study 17538085 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment (usual nonsurgical care)
Number of subjects: 304
Study 15155346 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine
Number of subjects: 54
Study 15155346 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 54
Study 11431663 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide 500 microg twice daily
Number of subjects: 122
Study 11431663 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg three times a day
Number of subjects: 122
Study 11431663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 9529685 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral terbinafine 250 mg daily for 12 weeks
Number of subjects: 111
Study 9236419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with peripheral arterial disease (n=64)
Number of subjects: 128
Study 9236419 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (n=64)
Number of subjects: 128
Study 9236419 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major vascular events (n=8)
Number of subjects: 128
Study 2018012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR, 200 mg once daily
Number of subjects: 65
Study 2018012 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine retard 20 mg twice daily
Number of subjects: 65
Study 7037501 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoradrate 0.1%
Number of subjects: 49
Study 7037501 — intervention group
Group type: COMPARATOR
Intervention: Dithrocream 0.1%
Number of subjects: 49
Study 31089856 — intervention group
Group type: EXPERIMENTAL
Intervention: Productive failure (attempt to generate solutions before receiving instruction)
Number of subjects: 40
Study 31089856 — intervention group
Group type: COMPARATOR
Intervention: Direct instruction only
Number of subjects: 40
Study 28987039 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioceramic undershirt (EG)
Number of subjects: 39
Study 28987039 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (PG)
Number of subjects: 39
Study 25122521 — intervention group
Group type: EXPERIMENTAL
Intervention: REMau cognitive training programme for autobiographical memory
Number of subjects: 0
Study 25122521 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training programme focused on collective semantic memory
Number of subjects: 0
Study 23849046 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultations with a Cardiometabolic Health Nurse
Number of subjects: 0
Study 23849046 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22091554 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermeasure groups with 50% and 75% irrelevant stimuli
Number of subjects: 0
Study 22091554 — intervention group
Group type: COMPARATOR
Intervention: Simple guilty (no countermeasure use)
Number of subjects: 0
Study 22091554 — intervention group
Group type: COMPARATOR
Intervention: Innocent subjects
Number of subjects: 0
Study 19284108 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoaeroionotherapy
Number of subjects: 0
Study 19284108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of magnetopuncture and phytoaeroionotherapeutic chronocorrection
Number of subjects: 0
Study 19284108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of soft‐tissue manual therapy
Number of subjects: 0
Study 17547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 108
Study 17547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 108
Study 17547587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 17547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (600 and 300 mg/day)
Number of subjects: 108
Study 17547587 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 108
Study 14999693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ofloxacin 200 mg i.v. q12h for 2 days followed by oral ofloxacin 200 mg q12h for 5 days)
Number of subjects: 120
Study 14999693 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 120
Study 14999693 — intervention group
Group type: COMPARATOR
Intervention: On-demand antibiotics
Number of subjects: 120